Allergan Comments On Pershing Square's Delivery Of Additional Requests From Stockholders Owning 1.5% Of Allergan's Shares

Allergan, Inc.

(“Allergan” or the “Company”) today commented on Pershing Square Capital Management, L.P.'s (“Pershing Square”) delivery of additional requests from stockholders owning 1.5% of Allergan's shares to call a Special Meeting of Stockholders (the “Special Meeting”). Allergan will review these requests in addition to the requests from stockholders owning 2.8% of Allergan's shares that were delivered on September 3, 2014. The Company issued the following statement: Notwithstanding Pershing Square and Valeant Pharmaceuticals International, Inc.'s (“Valeant”) efforts to change the subject, Allergan recognizes that what actually matters is value, and that's what the Company is focusing on delivering to stockholders. In that regard, Allergan's current strategic plan (2014 through 2019) is expected to deliver a compounded annual growth rate of greater than 20% EPS growth, including estimated 2016 EPS at approximately $10.00. Allergan has already scheduled the Special Meeting for December 18, 2014. As such, the delivery of additional requests for the Special Meeting by Pershing Square is not a meaningful development. The lawsuit in California is seeking an order barring Valeant, Pershing Square, Mr. Ackman, and entities affiliated with them from voting shares that Allergan believes were acquired in violation of the federal securities laws, including insider trading. If Allergan's motion for a preliminary injunction is granted, it would prevent Valeant, Pershing Square, and Mr. Ackman from voting their shares at any meeting of stockholders. Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins, Richards, Layton & Finger, P.A. and Wachtell, Lipton, Rosen & Katz are serving as legal counsel to the Company.